CD8A and melanoma: Recently, Sharma et al. analyzed TILs from paired pre- and post-ipilimumab-treated melanoma tissues for the expression of multiple TIL markers and showed that ipilimumab increased the frequency of CD8+ and CD4+ T cells but not FOXP3+ Treg cells [29].